Crisan Dan C, Papurica Marius, Rogobete Alexandru F, Cradigati Carmen A, Sarandan Mirela, Dumache Raluca, Bratu Lavinia M, Popovici Sonia E, Sandesc Dorel, Vernic Corina, Bedreag Ovidiu H
Clin Lab. 2016 Aug 1;62(8):1405-1411. doi: 10.7754/Clin.Lab.2016.160138.
A high percentage of critically ill polytrauma patients develop acute respiratory distress syndrome (ARDS), both because of the primary traumatic injuries and because of the secondary post-traumatic injuries. For adequate management of these patients, new complex evaluation and monitoring methods are needed, methods that could answer as many questions as possible regarding the pathophysiological changes associated with ARDS. Currently, a series of clinical and biochemical markers are being used which unfortunately do not respond to the needs of an intensive care clinician. Therefore, the changes of miRNAs have been intensely researched in the case of patients with ARDS. Moreover, using them as biomarkers for ARDS brings a series of answers regarding the pathophysiological changes associated to ARDS, making them biomarkers of the future in laboratory medicine.
In order for this research study to be carried out the literature found on Scopus and PubMed on the topic was consulted, up to the year 2015. The key words used for the articles were "acute respiratory distress syndrome ARDS", "biomarkers for ARDS", "critically ill polytrauma patients", "miRNAs expression in ARDS", "miRNAs expression in sepsis", "miRNAs in critically ill patients" and "miRNAs biomarker". Research articles in English, German, and French were included in the search.
Following the search using the above mentioned key words, 567 articles were found. After a rigorous analysis of these articles 55 of them were selected for our study.
Using miRNAs for the evaluation and monitoring of ARDS makes them a biomarker of the future, because of the complex answers they bring to questions related both to the main injury caused by ARDS and to the associated pathophysiology.
高比例的重症多发伤患者会发生急性呼吸窘迫综合征（ARDS），这既是由于原发性创伤损伤，也是由于创伤后继发性损伤。为了对这些患者进行充分管理，需要新的复杂评估和监测方法，这些方法能够回答尽可能多的与ARDS相关的病理生理变化问题。目前，正在使用一系列临床和生化标志物，但遗憾的是，这些标志物无法满足重症监护临床医生的需求。因此，ARDS患者中miRNAs的变化已得到深入研究。此外，将它们用作ARDS的生物标志物，为与ARDS相关的病理生理变化带来了一系列答案，使其成为未来检验医学中的生物标志物。
为了开展本研究，查阅了截至2015年在Scopus和PubMed上找到的关于该主题的文献。用于文章的关键词有“急性呼吸窘迫综合征ARDS”、“ARDS的生物标志物”、“重症多发伤患者”、“ARDS中的miRNAs表达”、“脓毒症中的miRNAs表达”、“重症患者中的miRNAs”以及“miRNAs生物标志物”。检索纳入了英文、德文和法文的研究文章。
使用上述关键词进行检索后，共找到567篇文章。在对这些文章进行严格分析后，选取了其中55篇用于我们的研究。
使用miRNAs评估和监测ARDS，使其成为未来的生物标志物，因为它们为与ARDS所致主要损伤及相关病理生理学相关的问题带来了复杂的答案。
